Detalhe da pesquisa
1.
Validation and Reference Scores of the Transition Readiness Assessment Questionnaire in Adolescent and Young Adult IBD Patients.
J Pediatr Gastroenterol Nutr
; 77(3): 381-388, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37347146
2.
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Gut
; 71(1): 34-42, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33384335
3.
Rotterdam Transition Test: A Valid Tool for Monitoring Disease Knowledge in Adolescents With Inflammatory Bowel Disease.
J Pediatr Gastroenterol Nutr
; 74(1): 60-67, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34371508
4.
Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
Eur J Pediatr
; 181(8): 3055-3065, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672586
5.
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Aliment Pharmacol Ther
; 59(12): 1510-1520, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644588
6.
Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.
J Crohns Colitis
; 17(8): 1262-1277, 2023 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36934327
7.
Self-efficacy in adolescents with inflammatory bowel disease: a pilot study of the "IBD-yourself", a disease-specific questionnaire.
J Crohns Colitis
; 7(9): e375-85, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23537816